The Next-generation Biotech Company
  • Develop innovative therapeutics to conquer ‘undruggable’ targets or create highly differentiated value.
  • Transform novel drug design by characterizing protein-protein interaction(PPI).
  • Demonstrated the power of the PPI-based platform with the integration of AI, biophysics & high-throughput experiments in terms of balanced in-house & partnered portfolios.

Development

  • 2018
    Company establised;
    Millions of dollars in first-round financing led by 5Y capital and ZhenFund.
  • 2019
    1st Place of Fosun " InnoStar " Entrepreneurship Competition
    Selected into Merck Accelerator Program
  • 2020
    $10 million pre-A round financing led by Sequoia China and Vision Plus Capital
    Selected into Johnson & Johnson JLABS
    First Prize of HICOOL Innovation & Entrepreneurship Competition
    Best Innovation Award in MIT Technology Review China
  • 2021
    $30 million Round A financing led by Sky9 Capital and 5Y Capital
    Series A+ financing round of tens of millions of dollars led by Genesis Capital and LYFE Capital
    1st Place of TI50 ( ’s 50 Most Promising Startups) China
    1st Place of LEO Pharma Innovation Competition
    Selected into Microsoft Accelerator and AstraZeneca iCampus
    Built collaborative pipelines with pharmaceutical companies such as I-mab Biopharma (NASDAQ:IMAB), TopAlliance (1877.HK), etc.
  • 2022
    Built collaborative pipelines with pharmaceutical companies such as WuXi Biologics, Kactus Biosystems, etc.
    Recognized as a high-tech enterprise in China

Leadership

Investors

Awards